Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 44 (2) , 231-239
- https://doi.org/10.1016/j.lungcan.2003.11.006
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Weekly, high‐dose paclitaxel in advanced lung carcinomaCancer, 2003
- Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*Chest, 2003
- Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trialLung Cancer, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Weekly paclitaxel in advanced non[ndash ]small cell lung cancerSeminars in Oncology, 2001
- Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A ReviewJournal of Clinical Oncology, 2000
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995